n-methylisoindigotin has been researched along with indirubin in 5 studies
Studies (n-methylisoindigotin) | Trials (n-methylisoindigotin) | Recent Studies (post-2010) (n-methylisoindigotin) | Studies (indirubin) | Trials (indirubin) | Recent Studies (post-2010) (indirubin) |
---|---|---|---|---|---|
34 | 0 | 11 | 347 | 3 | 184 |
Protein | Taxonomy | n-methylisoindigotin (IC50) | indirubin (IC50) |
---|---|---|---|
Glycogen synthase kinase-3 beta | Sus scrofa (pig) | 1 | |
[Tau protein] kinase | Sus scrofa (pig) | 1 | |
Cyclin-dependent kinase 14 | Homo sapiens (human) | 2.2 | |
G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 8.25 | |
Epidermal growth factor receptor | Homo sapiens (human) | 2 | |
Insulin receptor | Homo sapiens (human) | 2 | |
Cyclin-dependent kinase 1 | Homo sapiens (human) | 7.74 | |
Cyclin-dependent kinase 4 | Homo sapiens (human) | 2.2 | |
G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 8.8333 | |
G2/mitotic-specific cyclin-B | Marthasterias glacialis (spiny starfish) | 1 | |
Cyclin-A2 | Homo sapiens (human) | 3.525 | |
Cyclin-dependent kinase 11B | Homo sapiens (human) | 2.2 | |
Kit ligand | Homo sapiens (human) | 2 | |
G1/S-specific cyclin-E1 | Homo sapiens (human) | 4.85 | |
Cyclin-dependent kinase 2 | Homo sapiens (human) | 3.24 | |
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 2 | |
Cyclin-dependent kinase 8 | Homo sapiens (human) | 2.2 | |
Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 1.5 | |
Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.8515 | |
Cyclin-dependent kinase 7 | Homo sapiens (human) | 2.2 | |
Cyclin-dependent kinase 9 | Homo sapiens (human) | 2.2 | |
Cyclin-dependent kinase 3 | Homo sapiens (human) | 2.2 | |
Cyclin-dependent kinase 6 | Homo sapiens (human) | 2.2 | |
Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 6.15 | |
Cyclin-dependent kinase 16 | Homo sapiens (human) | 2.2 | |
Cyclin-dependent kinase 17 | Homo sapiens (human) | 2.2 | |
Cyclin-dependent kinase 18 | Homo sapiens (human) | 2.2 | |
Cyclin-dependent kinase 13 | Homo sapiens (human) | 2.2 | |
Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 6.7143 | |
Cyclin-dependent kinase 10 | Homo sapiens (human) | 2.2 | |
Cyclin-dependent kinase 20 | Homo sapiens (human) | 2.2 | |
G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 8.25 | |
Cyclin-dependent kinase 15 | Homo sapiens (human) | 2.2 | |
Cyclin-dependent kinase 19 | Homo sapiens (human) | 2.2 | |
Cyclin-dependent kinase 1 | Oryzias latipes (Japanese medaka) | 1 | |
Cyclin-dependent kinase 12 | Homo sapiens (human) | 2.2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, RH; Ji, XJ; Li, K; Liu, XM; Wang, LG | 1 |
Gao, BH; Liu, JZ; Wu, GY | 1 |
Hao, Y; Liu, B; Qian, L; Xiao, Z | 1 |
Chen, F; Hou, M; Ji, C; Li, L; Ma, D; Sun, J; Yan, S; Zhang, M | 1 |
Deng, X; Gao, Q; Gao, X; Gu, L; Wang, Q; Wang, Y; Xiong, X; Ye, B; Zeng, Z | 1 |
1 review(s) available for n-methylisoindigotin and indirubin
Article | Year |
---|---|
Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Blast Crisis; China; Dose-Response Relationship, Drug; Humans; Hydroxyurea; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Chemical; Time Factors; Treatment Outcome | 2002 |
4 other study(ies) available for n-methylisoindigotin and indirubin
Article | Year |
---|---|
Pharmacological studies of meisoindigo: absorption and mechanism of action.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Indoles; Rats | 1991 |
[Studies on the mechanism of antitumor action of Dian III].
Topics: Animals; Antineoplastic Agents; DNA; Indoles; Kinetics; Mice; Rats; Thymidine; Uridine | 1984 |
Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment.
Topics: Adult; Benzamides; Cytogenetic Analysis; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction | 2010 |
Meisoindigo, but not its core chemical structure indirubin, inhibits zebrafish interstitial leukocyte chemotactic migration.
Topics: Animals; Animals, Genetically Modified; Anti-Inflammatory Agents; Chemotaxis, Leukocyte; Disease Models, Animal; Dose-Response Relationship, Drug; Green Fluorescent Proteins; Indoles; Inflammation; Leukocytes; Molecular Structure; Signal Transduction; Structure-Activity Relationship; Time Factors; Zebrafish | 2017 |